IRVING, Texas and PHOENIX, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Caris Diagnostics ("Caris Dx") -- a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology -- today announced the appointment of Jerry Martino as Senior Vice President, Chief Financial Officer. Mr. Martino will provide executive leadership for the customary financial functions of the company, as well as strategic guidance for integrated corporate functions that serve all business groups. Additionally, Mr. Martino will help to shape the international strategy for the company.
Jerry brings extensive international and domestic business leadership experience to Caris. Most recently, he was the Executive Vice President and Chief Operating Officer for Par Pharmaceutical Companies. In this role, his responsibilities included all financial reporting, treasury, investor relations, contracts and pricing, internal audit, information technology, human resources and supply chain activities. Previously, Jerry was with Schering-Plough Corporation for twelve years, most recently as Vice President, Global Materials Management and Global Supply Chain Operations.
"In addition to his deep knowledge of finance and operations garnered from his years in the pharmaceutical sector, Jerry possesses extraordinary leadership skills that will be a superb addition to the Caris Dx management team. He will provide invaluable guidance as our organization sets the standard for molecular diagnostics and personalized medicine services," said David D. Halbert, Chairman and CEO of Caris Dx.
"I am very excited to join Caris as Chief Financial Officer. Caris has proven itself to be a leader in anatomic pathology and clinically-validated molecular diagnostics. Having spent my career in many areas of finance and operational roles, I look forward to working with the management team to establish a financial infrastructure that will further the company's success," commented Mr. Martino.
Jerry is a graduate of Montclair State University and is a Certified Public Accountant.
About Caris Diagnostics
Caris Dx is a U.S.-based biosciences company specializing in the development and commercialization of clinically-validated molecular diagnostics and anatomic pathology services primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Dx also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Biopsies for more than 2,700 patients are received daily for analysis by Caris from physicians nationally. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites) and Newton, Massachusetts. Additional information is available at www.carisdx.com.